Solesence earnings release, May 12, 2026

Solesence, Inc. (SLSN) · Form 8-K, Item 2.02 · Filed · SEC filing

Solésence Reports First Quarter 2026 Financial Results

Advances implementation of Transform and Transcend strategic initiative across Operational Excellence and New Technology Commercialization

ROMEOVILLE, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2026.

“In March, we introduced Transform and Transcend to our investor community, the strategic initiative that we began at the end of 2025,” commented Kevin Cureton, President and Chief Executive Officer. “Our first quarter results reflect our disciplined execution on this initiative, particularly on our first and foundational pillar, operational excellence. Combined with steady early progress in our efforts to further leverage our intellectual property, expand our addressable market, and evolve our service model to capture greater share of the value chain, Solésence is well positioned to drive long-term, sustainable profitability and growth.”

Recent Highlights and Accomplishments

Improved gross margin through disciplined execution of first pillar of Transform & Transcend Initiative: Operational Excellence.

Expanded OTC claims with commercialization of new platform technologies: WHSPR™ and Chromalüm™.

Added financial executive Marc James as new independent Director.

Laura Riffner, Chief Financial Officer, added, “In the first quarter, Solésence’s investments focused on its operational infrastructure, including employee training and organizational restructuring which created near-term pressure on profitability but also resulted in improved efficiency and reduced labor costs across the business. We expect this will position us for improved operational and financial results as we move through the year.”

First Quarter 2026 Financial Highlights

Revenue for the first quarter was $13.0 million, compared to $14.6 million for the same period in 2025.

Gross profit in the first quarter was $3.3 million, compared to $3.4 million for the same period in 2025.

Gross margin in the first quarter was 26%, compared to 23% for the same period in 2025.

Net loss for the first quarter was approximately $0.8 million, compared to net income of approximately $0.08 million for the same period in 2025.

Conference Call

Solésence will host its first quarter conference call on Tuesday, May 12, 2026, at 7:30 a.m. CT, 8:30 a.m. ET, to discuss its financial results and provide a business and financial update. On the call will be Kevin Cureton, President and Chief Executive Officer, and Laura Riffner, Chief Financial Officer.

Webcast Link: https://edge.media-server.com/mmc/p/t9uyyvcs

Dial-In Link: https://register-conf.media-server.com/register/BI8309d9a33aea468ab429e32ef4434b33

To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the option to have the system dial-out to you once the conference call begins. If you forget your PIN prior to the conference call, you can simply re-register.

The call may also be accessed through the Company’s investor relations website, at https://ir.solesence.com/. Please join the conference call at least five minutes before the start time.

FINANCIAL RESULTS AND NON-GAAP INFORMATION

Use of Non-GAAP Financial Information

Solésence believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, Generally Accepted Accounting Principles (“GAAP”) and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with GAAP.

About Solésence, Inc.

Solésence, Inc. (Nasdaq: SLSN) is a leader in scientifically-driven health care solutions across beauty and life science categories. With a mission to deliver joy through innovation, inclusivity and the science of beautiful skin, we have redefined mineral-based sun protection by maximizing transparency, effectiveness, aesthetics, and wearability — empowering individuals to embrace beauty on their own terms. Combining best-in-class skin health solutions with the celebration of self-care, we allow brands to deliver unique product claims and attributes by seamlessly integrating protection, prevention, and treatment technologies into daily use products. Learn more at solesence.com.

Financial statements

Income Statement

SOLESENCE, INC — investors@solesence.com (in thousands except share and per share data)

SOLESENCE, INC – CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited Consolidated Condensed) – Three months ended – March 31, – 2026Three months ended – March 31, – 2026SOLESENCE, INC – CONSOLIDATED STATEMENTS OF OPERATIONS – (Unaudited Consolidated Condensed) – Three months ended – March 31, – 2025Three months ended – March 31, – 2025
Revenue:Product revenue12,91914,575
Revenue:Other revenue3850
Revenue:Net revenue12,95714,625
Revenue:Cost of revenue9,62011,243
Revenue:Gross profit3,3373,382
Operating expense:Research and development expense1,0421,018
Operating expense:Selling, general and administrative expense2,7992,108
Operating expense:Net (loss) income from operations-504256
Interest incomeInterest expense263176
Interest incomeOther nonoperating income1
Interest incomeNet (loss) income before provision for income taxes-76680
Interest incomeNet (loss) income-76680
Interest incomeNet (loss) income per share-basic-0.01$-
Interest incomeWeighted average number of common shares outstanding - basic70,625,49470,103,279
Interest incomeNet (loss) income per share-diluted-0.01$-
Interest incomeWeighted average number of common shares outstanding - diluted70,625,49472,632,116
Interest incomeSOLESENCE, INCSOLESENCE, INC
Interest incomeCONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULECONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE
Interest income(Unaudited Consolidated Condensed)(Unaudited Consolidated Condensed)
Interest income(in thousands except share and per share data)(in thousands except share and per share data)
Revenue:Product revenue12,91914,575
Revenue:Other revenue3850
Revenue:Net revenue12,95714,625
Cost of revenue detail:Depreciation302216
Cost of revenue detail:Non-Cash equity compensation2027
Cost of revenue detail:Other costs of revenue9,29811,000
Cost of revenue detail:Cost of revenue9,62011,243
Cost of revenue detail:Gross profit3,3373,382
Research and development expense detail:Depreciation44
Research and development expense detail:Non-Cash equity compensation1827
Research and development expense detail:Other research and development expense1,020987
Research and development expense detail:Research and development expense1,0421,018
Selling, general and administrative expense detail:Depreciation and amortization66
Selling, general and administrative expense detail:Non-Cash equity compensation4673
Selling, general and administrative expense detail:Other selling, general and administrative expense2,7472,029
Selling, general and administrative expense detail:Selling, general and administrative expense2,7992,108
Selling, general and administrative expense detail:Net (loss) income from operations-504256
Interest incomeInterest expense263176
Interest incomeOther nonoperating income1
Interest incomeNet (loss) income before provision for income taxes-76680
Interest incomeNet (loss) income-76680
Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):Addback Interest, net263176
Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):Addback Depreciation/Amortization312226
Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):Addback Non-Cash Equity Compensation84127
Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):Adjusted EBITDA-107609

Balance Sheet

SOLESENCE, INC — investors@solesence.com (in thousands)

SOLESENCE, INC – CONSOLIDATED BALANCE SHEETS – (Unaudited Consolidated Condensed) – March 31, – 2026 – (Unaudited)SOLESENCE, INC – CONSOLIDATED BALANCE SHEETS – (Unaudited Consolidated Condensed) – December 31, – 2025
Current assets:Cash5731,288
Current assets:Trade accounts receivable7,2467,642
Current assets:Allowance for credit losses-867-806
Current assets:Trade accounts receivable, net6,3796,836
Current assets:Inventories, net17,55918,511
Current assets:Prepaid expenses and other current assets1,9022,141
Current assets:Total current assets26,41328,776
Current assets:Equipment and leasehold improvements, net14,74614,329
Current assets:Operating leases, right of use6,5986,913
Current assets:Other assets, net3737
Current assets:Total assets47,79450,055
Current liabilities:Line of credit, accounts receivable, related party3,0474,767
Current liabilities:Current portion of operating lease obligations1,2961,255
Current liabilities:Accounts payable4,6724,098
Current liabilities:Deferred revenue1,165930
Current liabilities:Accrued expenses2,5112,879
Current liabilities:Total current liabilities12,69113,929
Current liabilities:Long-term portion of operating lease obligations7,4407,798
Current liabilities:Long-term portion of line of credit, inventory, related party9,5009,500
Current liabilities:Long-term portion of debt, related parties1,0001,000
Current liabilities:Asset retirement obligations196194
Current liabilities:Total long-term liabilities18,13618,492
Full release

Forward-Looking Statements... (truncated) mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 31, 2026. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.

Media Contact: media@solesence.com

Investor Relations Contact: investors@solesence.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Solesence earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.